These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 29421573

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X, Lv Y, Liu P, Li Z, Hu L, Zeng C, Yang L.
    Bioorg Med Chem Lett; 2016 Mar 15; 26(6):1571-1575. PubMed ID: 26879314
    [Abstract] [Full Text] [Related]

  • 4. Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumour activity as EGFRwt-TK inhibitor.
    Zhang Y, Chen L, Li X, Gao L, Hao Y, Li B, Yan Y.
    J Enzyme Inhib Med Chem; 2019 Dec 15; 34(1):1668-1677. PubMed ID: 31530043
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
    OuYang Y, Zou W, Peng L, Yang Z, Tang Q, Chen M, Jia S, Zhang H, Lan Z, Zheng P, Zhu W.
    Eur J Med Chem; 2018 Jun 25; 154():29-43. PubMed ID: 29775935
    [Abstract] [Full Text] [Related]

  • 7. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD, Fang F, Li JR, Du QR, Sun J, Gong HB, Zhu HL.
    Bioorg Med Chem Lett; 2012 Sep 15; 22(18):5870-5. PubMed ID: 22901387
    [Abstract] [Full Text] [Related]

  • 8. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W, Ren Y, Zhang Z, Sun H, Ma Y, Yan B.
    Bioorg Med Chem; 2018 May 01; 26(8):1740-1750. PubMed ID: 29523467
    [Abstract] [Full Text] [Related]

  • 9. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
    Qin X, Li Z, Yang L, Liu P, Hu L, Zeng C, Pan Z.
    Bioorg Med Chem; 2016 Jul 01; 24(13):2871-2881. PubMed ID: 27234887
    [Abstract] [Full Text] [Related]

  • 10. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
    Ahmed MF, Magdy N.
    Anticancer Agents Med Chem; 2017 Jul 01; 17(6):832-838. PubMed ID: 27671305
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
    Zhang Y, Zhang Y, Liu J, Chen L, Zhao L, Li B, Wang W.
    Bioorg Med Chem Lett; 2017 Apr 01; 27(7):1584-1587. PubMed ID: 28238614
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C, Xu S, Peng L, Zhang B, Zhang H, Hu Y, Zheng P, Zhu W.
    J Enzyme Inhib Med Chem; 2019 Dec 01; 34(1):203-217. PubMed ID: 30835140
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X, Peng T, Ji X, Li J, Tong L, Li Z, Yang W, Xu Y, Li M, Ding J, Jiang H, Xie H, Liu H.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7988-98. PubMed ID: 24183742
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis.
    El-Azab AS, Abdel-Aziz AA, AlSaif NA, Alkahtani HM, Alanazi MM, Obaidullah AJ, Eskandrani RO, Alharbi A.
    Bioorg Chem; 2020 Nov 15; 104():104345. PubMed ID: 33142413
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents.
    Hao S, Wang JH, Hou L, Liang JW, Yan JH, Niu YF, Li XY, Sun Q, Meng FH.
    Bioorg Chem; 2024 Oct 15; 151():107686. PubMed ID: 39111120
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
    Tu Y, Wang C, Xu S, Lan Z, Li W, Han J, Zhou Y, Zheng P, Zhu W.
    Bioorg Med Chem; 2017 Jun 15; 25(12):3148-3157. PubMed ID: 28428040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.